LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

doi:10.1007/s10549-018-4852-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Breast cancer research and treatment - 1 Oct 2018

Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey K

Abstract excerpt

PURPOSE: HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everolimus (E), a brain-permeable mTOR inhibitor, trastuzumab (T), and vinorelbine (V) in patients with HER2 + BCBM. PATIENTS AND METHODS: Eligible patients had...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Receptor, ErbB-2

Share to Survival Analysis

Share to Trastuzumab

Share to Vinorelbine

Source

Open in PubMed Open full text

Identifiers

PMID: 29938395
DOI: 10.1007/s10549-018-4852-5
PMCID: PMC6779035

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.PMID 29938395Read ↗

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.Semantic proximity Read ↗

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasisSemantic proximity Read ↗

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapiesSemantic proximity Read ↗

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.Semantic proximity Read ↗

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.Semantic proximity Read ↗

Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.Semantic proximity Read ↗

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: a case report and literature reviewSemantic proximity Read ↗

Genomic and immune profiling of breast cancer brain metastasesSemantic proximity Read ↗

Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Comprehensive molecular biomarker identification in breast cancer brain metastases.Semantic proximity Read ↗

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.